Compare · ARTV vs GILD
ARTV vs GILD
Side-by-side comparison of Artiva Biotherapeutics Inc. (ARTV) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARTV and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $155.26B, about 641.0x ARTV ($242.2M).
- Over the past year, ARTV is up 502.5% and GILD is up 16.7% - ARTV leads by 485.8 points.
- GILD has been more active in the news (17 items in the past 4 weeks vs 5 for ARTV).
- GILD has more recent analyst coverage (25 ratings vs 7 for ARTV).
- Company
- Artiva Biotherapeutics Inc.
- Gilead Sciences Inc.
- Price
- $9.79+4.59%
- $125.05+0.17%
- Market cap
- $242.2M
- $155.26B
- 1M return
- +22.84%
- -4.14%
- 1Y return
- +502.46%
- +16.66%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 1992
- News (4w)
- 5
- 17
- Recent ratings
- 7
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest ARTV
- Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- Director Ra Capital Management, L.P. bought $4,599,903 worth of shares (531,326 units at $8.66) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Artiva Biotherapeutics Inc.
- Director Ra Capital Management, L.P. bought $7,650,148 worth of shares (1,027,722 units at $7.44) (SEC Form 4)
- Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
- The $13 Million Company Teaching the Immune System to Hunt Cancer
- Large owner Gc Corp. bought $16,499,992 worth of shares (1,432,291 units at $11.52) (SEC Form 4)
- Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- SVP, Research and Development Raymon Heather sold $27,879 worth of shares (3,095 units at $9.01), decreasing direct ownership by 2% to 148,228 units (SEC Form 4) to satisfy withholding tax
- Chief Tech Operations Officer Horan Christopher sold $63,073 worth of shares (7,002 units at $9.01), decreasing direct ownership by 2% to 293,450 units (SEC Form 4) (for withholding tax)
Latest GILD
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
- Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
- Chief Medical Officer Berger Dietmar covered exercise/tax liability with 263 shares and converted options into 533 shares, increasing direct ownership by 1% to 19,252 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M converted options into 589 shares and covered exercise/tax liability with 283 shares, increasing direct ownership by 6% to 5,360 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 0.84% to 174,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna converted options into 2,796 shares and covered exercise/tax liability with 1,341 shares, increasing direct ownership by 1% to 127,234 units (SEC Form 4)
- Chairman & CEO O'Day Daniel Patrick converted options into 8,779 shares and covered exercise/tax liability with 4,213 shares, increasing direct ownership by 0.74% to 622,133 units (SEC Form 4)